Facultad de Farmacia y Bioquímica, Instituto de Química y Fisicoquímica Biológicas, Universidad de Buenos Aires, Buenos Aires, Argentina.
Am J Physiol Renal Physiol. 2012 Jun 15;302(12):F1606-15. doi: 10.1152/ajprenal.00063.2012. Epub 2012 Apr 4.
Angiotensin (ANG)-(1-7) is known to attenuate diabetic nephropathy; however, its role in the modulation of renal inflammation and oxidative stress in type 2 diabetes is poorly understood. Thus in the present study we evaluated the renal effects of a chronic ANG-(1-7) treatment in Zucker diabetic fatty rats (ZDF), an animal model of type 2 diabetes and nephropathy. Sixteen-week-old male ZDF and their respective controls [lean Zucker rats (LZR)] were used for this study. The protocol involved three groups: 1) LZR + saline, 2) ZDF + saline, and 3) ZDF + ANG-(1-7). For 2 wk, animals were implanted with subcutaneous osmotic pumps that delivered either saline or ANG-(1-7) (100 ng·kg(-1)·min(-1)) (n = 4). Renal fibrosis and tissue parameters of oxidative stress were determined. Also, renal levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), ED-1, hypoxia-inducible factor-1α (HIF-1α), and neutrophil gelatinase-associated lipocalin (NGAL) were determined by immunohistochemistry and immunoblotting. ANG-(1-7) induced a reduction in triglyceridemia, proteinuria, and systolic blood pressure (SBP) together with a restoration of creatinine clearance in ZDF. Additionally, ANG-(1-7) reduced renal fibrosis, decreased thiobarbituric acid-reactive substances, and restored the activity of both renal superoxide dismutase and catalase in ZDF. This attenuation of renal oxidative stress proceeded with decreased renal immunostaining of IL-6, TNF-α, ED-1, HIF-1α, and NGAL to values similar to those displayed by LZR. Angiotensin-converting enzyme type 2 (ACE2) and ANG II levels remained unchanged after treatment with ANG-(1-7). Chronic ANG-(1-7) treatment exerts a renoprotective effect in ZDF associated with a reduction of SBP, oxidative stress, and inflammatory markers. Thus ANG-(1-7) emerges as a novel target for treatment of diabetic nephropathy.
血管紧张素(ANG)-(1-7)已知可减轻糖尿病肾病;然而,其在 2 型糖尿病中调节肾脏炎症和氧化应激的作用知之甚少。因此,在本研究中,我们评估了慢性 ANG-(1-7)治疗在 2 型糖尿病和肾病动物模型 Zucker 糖尿病肥胖大鼠(ZDF)中的肾脏作用。使用 16 周龄雄性 ZDF 和各自的对照[瘦 Zucker 大鼠(LZR)]进行这项研究。该方案包括三组:1)LZR+盐水,2)ZDF+盐水,和 3)ZDF+ANG-(1-7)。在 2 周内,动物被植入皮下渗透泵,泵入盐水或 ANG-(1-7)(100ng·kg-1·min-1)(n=4)。测定肾纤维化和氧化应激组织参数。此外,通过免疫组化和免疫印迹测定肾组织中白细胞介素 6(IL-6)、肿瘤坏死因子-α(TNF-α)、ED-1、缺氧诱导因子-1α(HIF-1α)和中性粒细胞明胶酶相关脂质运载蛋白(NGAL)的水平。ANG-(1-7)诱导 ZDF 降低甘油三酯血症、蛋白尿和收缩压(SBP),并恢复肌酐清除率。此外,ANG-(1-7)降低肾纤维化,减少丙二醛反应物质,并恢复 ZDF 肾超氧化物歧化酶和过氧化氢酶的活性。这种肾脏氧化应激的衰减伴随着肾组织中 IL-6、TNF-α、ED-1、HIF-1α和 NGAL 的免疫染色减少,使其值与 LZR 相似。用 ANG-(1-7)治疗后,血管紧张素转换酶 2(ACE2)和 ANG II 水平保持不变。慢性 ANG-(1-7)治疗在 ZDF 中发挥肾脏保护作用,可降低 SBP、氧化应激和炎症标志物。因此,ANG-(1-7)成为治疗糖尿病肾病的新靶点。